Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)

BACKGROUND: To compare the efficacy and safety of CAPIRI+bevacizumab (Bev) in comparison with FOLFIRI+Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC). METHODS: Patients were randomised to receive either FOLFIRI plus Bev 5 mg kg(−1) every 2 weeks (Arm-A) or CAPIRI pl...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Souglakos, J, Ziras, N, Kakolyris, S, Boukovinas, I, Kentepozidis, N, Makrantonakis, P, Xynogalos, S, Christophyllakis, Ch, Kouroussis, Ch, Vamvakas, L, Georgoulias, V, Polyzos, A
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group 2012
Onderwerpen:
Clinical Studies
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3273357/
https://ncbi.nlm.nih.gov/pubmed/22240792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.594
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items